Targeted delivery of chemotherapeutic agents is a new approach for the treatment of cancer, which provides increased selectivity and decreased systemic toxicity. We have recently developed a promising drug delivery system, in which the anticancer drug daunorubicin (Dau) was attached via oxime bond to a gonadotropin-releasing hormone-III (GnRH-III) derivative used as a targeting moiety (Glp-His-Trp-Lys(Ac)-His-Asp-Trp-Lys(Dau = Aoa)-Pro-Gly-NH2; Glp = pyroglutamic acid, Ac = acetyl; Aoa = aminooxyacetyl). This bioconjugate exerted in vitro cytostatic/cytotoxic effect on human breast, prostate and colon cancer cells, as well as significant in vivo tumor growth inhibitory effect on colon carcinoma bearing mice. In our previous studies, H-Lys(Dau = Aoa)-OH was identified as the smallest metabolite produced in the presence of rat liver lysosomal homogenate, which was able to bind to DNA in vitro. To get a deeper insight into the mechanism of action of the bioconjugate, changes in the protein expression profile of HT-29 human colon cancer cells after treatment with the bioconjugate or free daunorubicin were investigated by mass spectrometry-based proteomics. Our results indicate that several metabolism-related proteins, molecular chaperons and proteins involved in signaling are differently expressed after targeted chemotherapeutic treatment, leading to the conclusion that the bioconjugate exerts its cytotoxic action by interfering with multiple intracellular processes.
References
[1]
Nagy A, Schally AV (2005) Targeting cytotoxic conjugates of somatostatin, luteinizing hormone-releasing hormone and bombesin to cancers expressing their receptors: a “smarter” chemotherapy. Curr Pharm Des 11: 1167–1180. doi: 10.2174/1381612053507594
[2]
Mez？ G, Manea M (2010) Receptor-mediated tumor targeting based on peptide hormones Expert Opin Drug Deliv. 7: 79–96. doi: 10.1517/17425240903418410
[3]
Majumdar S, Siahaan TJ (2012) Peptide-mediated targeted drug delivery. Med Res Rev 32: 637–658. doi: 10.1002/med.20225
[4]
Limonta P, Montagnani Marelli M, Mai S, Motta M, Martini L, et al. (2012) GnRH receptors in cancer: from cell biology to novel targeted therapeutic strategies. Endocr Rev 33: 784–811. doi: 10.1210/er.2012-1014
[5]
Westphalen S, Kotulla G, Kaiser F, Krauss W, Werning G, et al. (2000) Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines. Int J Oncol 17: 1063–1069. doi: 10.3892/ijo.17.5.1063
[6]
Engel J, Emons G, Pinski J, Schally AV (2012) AEZS-108: a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors. Expert Opin Investig Drugs 21: 891–899. doi: 10.1517/13543784.2012.685128
[7]
Lovas S, Pályi I, Vincze B, Horváth J, Kovács M, et al. (1998) Direct anticancer activity of gonadotropin-releasing hormone-III. J Pept Res 52: 384–389. doi: 10.1111/j.1399-3011.1998.tb00662.x
[8]
Kovács M, Sepr？di J, Koppán M, Horváth JE, Vincze B, et al. (2002) Lamprey gonadotropin hormone-releasing hormone-III has no selective follicle-stimulating hormone-releasing effect in rats, J Neuroendocrinol. 14: 647–655. doi: 10.1046/j.1365-2826.2002.00828.x
[9]
Manea M, Mez？ G (2013) lGnRH-III - a promising candidate for anticancer drug development. Protein Pept Lett 20: 439–449. doi: 10.2174/092986613805290381
[10]
Orbán E, Mez？ G, Schlage P, Csík G, Kuli？ Z, et al. (2011) In vitro degradation and antitumor activity of oxime bond-linked daunorubicin-GnRH-III bioconjugates and DNA-binding properties of daunorubicin-amino acid metabolites. Amino Acids 41: 469–483. doi: 10.1007/s00726-010-0766-1
[11]
Schlage P, Mez？ G, Orbán E, B？sze S, Manea M (2011) Anthracycline-GnRH derivative bioconjugates with different linkages: synthesis, in vitro drug release and cytostatic effect. J Control Release 156: 170–178. doi: 10.1016/j.jconrel.2011.08.005
[12]
Manea M, Tóvári J, Tejeda M, Schulcz A, Kapuvári B, et al. (2012) In-vivo antitumour effect of daunorubicin-GnRH-III derivative conjugates on colon carcinoma-bearing mice. Anticancer Drugs 23: 90–97. doi: 10.1097/cad.0b013e32834bb6b4
[13]
Manea M, Leurs U, Orbán E, Baranyai Z, ？hlschl？ger P, et al. (2011) Enhanced enzymatic stability and antitumor activity of daunorubicin-GnRH-III bioconjugates modified in position 4. Bioconjug Chem 22: 1320–1329. doi: 10.1021/bc100547p
[14]
Riddick DS, Lee C, Ramji S, Chinje EC, Cowen RL, et al. (2005) Cancer chemotherapy and drug metabolism. Drug Metab Dispos 33: 1083–1096. doi: 10.1124/dmd.105.004374
[15]
Gewirtz DA (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57: 727–741. doi: 10.1016/s0006-2952(98)00307-4
[16]
Orbán E, Manea M, Marquadt A, Bánóczi Z, Csík G, et al. (2011) A new daunomycin-peptide conjugate: synthesis, characterization and the effect on the protein expression profile of HL-60 cells in vitro. Bioconjug Chem 22: 2154–2165. doi: 10.1021/bc2004236
[17]
Sarto C, Binz PA, Mocarelli P (2000) Heat shock proteins in human cancer. Electrophoresis 21: 1218–1226. doi: 10.1002/(sici)1522-2683(20000401)21:6<1218::aid-elps1218>3.3.co;2-8
[18]
Musch MW, Kaplan B, Chang EB (2001) Role of Increased Basal Expression of Heat Shock Protein 72 in Colonic Epithelial c2BBE Adenocarcinoma Cells. Cell Growth and Differentiation 12: 419–426.
[19]
Grivicich I, Regner A, Zanoni C, Correa LP, Jotz GP, et al. (2007) Hsp70 response to 5-fluorouracil treatment in human colon cancer cell lines. Int J Colorectal Dis 22: 1201–1208. doi: 10.1007/s00384-007-0307-x
[20]
Goloudina AR, Demidov ON, Garrido C (2012) Inhibition of HSP70: a challenging anti-cancer strategy. Cancer Lett 325: 117–124. doi: 10.1016/j.canlet.2012.06.003
[21]
Balaburski GM, Leu JI, Beeharry N, Hayik S, Andrake MD, et al. (2013) A modified HSP70 inhibitor shows broad activity as an anticancer agent. Mol Cancer Res 11: 219–229. doi: 10.1158/1541-7786.mcr-12-0547-t
[22]
Didelot C, Lanneau D, Brunet M, Joly AL, De Thonel A, et al. (2007) Anti-cancer therapeutic approaches based on intracellular and extracellular heat shock proteins. Curr Med Chem 14: 2839–2847. doi: 10.2174/092986707782360079
[23]
Zamanian M, Veerakumarasivam A, Abdullah S, Rosli R (2013) Calreticulin and Cancer. Pathol Oncol Res 19: 149–154. doi: 10.1007/s12253-012-9600-2
[24]
Ataman-Onal Y, Beaulieu C, Busseret S, Charrier J-P, Choquet-Kastylevsky G, et al.. (2011) Protein disulfide isomerase assay method for the in vitro diagnosis of colorectal cancer. US20110104701 A1.
[25]
Zhong S, Ye W, Lin SH, Liu JY, Leong J, et al. (2011) Zeranol induces cell proliferation and protein disulfide isomerase expression in mammary gland of ACI rat. Anticancer Res 31: 1659–1665.
[26]
Goplen D, Wang J, Enger P？, Tysnes BB, Terzis AJ, et al. (2006) Protein disulfide isomerase expression is related to the invasive properties of malignant glioma. Cancer Res 66: 9895–9902. doi: 10.1158/0008-5472.can-05-4589
[27]
Egger S, Chaikuad A, Kavanagh KL, Oppermann U, Nidetzky B (2010) UDP-glucose dehydrogenase: structure and function of a potential drug target. Biochem Soc Trans 38: 1378–1385. doi: 10.1042/bst0381378
[28]
Wang TP, Pan YR, Fu CY, Chang HY (2010) Down-regulation of UDP-glucose dehydrogenase affects glycosaminoglycans synthesis and motility in HCT-8 colorectal carcinoma cells. Exp Cell Res 316: 2893–2902. doi: 10.1016/j.yexcr.2010.07.017
[29]
Ropponen K, Tammi M, Parkkinen J, Eskelinen M, Tammi R, et al. (1998) Tumor cell-associated hyaluronan as an unfavorable prognostic factor in colorectal cancer. Cancer Res 58: 342–347.
[30]
Furuhashi M, Hotamisligil GS (2008) Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov 7: 489–503. doi: 10.1038/nrd2589
[31]
Junqin L, Qing L, Xiaodong W, Huijun Y, Hua L (2012) The study of fatty acid binding protein expression in human breast cancer tissue and its significance. J Biosci Med 2: 1.
[32]
Li Z, Huang C, Bai S, Pan X, Zhou R, et al. (2008) Prognostic evaluation of epidermal fatty acid-binding protein and calcyphosine, two proteins implicated in endometrial cancer using a proteomic approach. Int J Cancer 123: 2377–2383. doi: 10.1002/ijc.23808
[33]
Sinha P, Hütter G, K？ttgen E, Dietel M, Schadendorf D, et al. (1999) Increased expression of epidermal fatty acid binding protein, cofilin, and 14-3-3-sigma (stratifin) detected by two-dimensional gel electrophoresis, mass spectrometry and microsequencing of drug-resistant human adenocarcinoma of the pancreas. Electrophoresis 20: 2952–2960. doi: 10.1002/(sici)1522-2683(19991001)20:14<2952::aid-elps2952>3.0.co;2-h
[34]
Nagai M, Yoneda Y (2012) Small GTPase Ran and Ran-binding proteins. BioMol Concepts 3: 307–318. doi: 10.1515/bmc-2011-0068
[35]
Rensen WM, Roscioli E, Tedeschi A, Mangiacasale R, Ciciarello M, et al. (2009) RanBP1 downregulation sensitizes cancer cells to taxol in a caspase-3-dependent manner. Oncogene 28: 1748–1758. doi: 10.1038/onc.2009.24
[36]
Cao XX, Xu JD, Xu JW, Liu XL, Cheng YY, et al. (2010) RACK1 promotes breast carcinoma proliferation and invasion/metastasis in vitro and in vivo. Breast Cancer Res Treat 123: 375–386. doi: 10.1007/s10549-009-0657-x
[37]
Berns H, Humar R, Hengerer B, Kiefer FN, Battegay EJ (2000) RACK1 is up-regulated in angiogenesis and human carcinomas. FASEB J 14: 2549–2558. doi: 10.1096/fj.99-1038com
